[go: up one dir, main page]

AU727939B2 - A method of treating cancer - Google Patents

A method of treating cancer Download PDF

Info

Publication number
AU727939B2
AU727939B2 AU27221/97A AU2722197A AU727939B2 AU 727939 B2 AU727939 B2 AU 727939B2 AU 27221/97 A AU27221/97 A AU 27221/97A AU 2722197 A AU2722197 A AU 2722197A AU 727939 B2 AU727939 B2 AU 727939B2
Authority
AU
Australia
Prior art keywords
substituted
glycyl
aryl
unsubstituted
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU27221/97A
Other languages
English (en)
Other versions
AU2722197A (en
Inventor
David C. Heimbrook
Allen I. Oliff
Steven M. Stirdivant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9613599.1A external-priority patent/GB9613599D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2722197A publication Critical patent/AU2722197A/en
Application granted granted Critical
Publication of AU727939B2 publication Critical patent/AU727939B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AU27221/97A 1996-04-03 1997-03-31 A method of treating cancer Ceased AU727939B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1477396P 1996-04-03 1996-04-03
US60/014773 1996-04-03
GB9613599 1996-06-28
GBGB9613599.1A GB9613599D0 (en) 1996-06-28 1996-06-28 A method of treating cancer
PCT/US1997/005328 WO1997036587A1 (fr) 1996-04-03 1997-03-31 Methode de traitement du cancer

Publications (2)

Publication Number Publication Date
AU2722197A AU2722197A (en) 1997-10-22
AU727939B2 true AU727939B2 (en) 2001-01-04

Family

ID=26309586

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27221/97A Ceased AU727939B2 (en) 1996-04-03 1997-03-31 A method of treating cancer

Country Status (5)

Country Link
EP (1) EP0906099A4 (fr)
JP (1) JP2000504023A (fr)
AU (1) AU727939B2 (fr)
CA (1) CA2250232A1 (fr)
WO (1) WO1997036587A1 (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
WO1998007425A1 (fr) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Composes d'imidazole, compositions les contenant et leur utilisation
WO1998056377A1 (fr) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Nouveaux composes de pyrazole et de pyrazoline substitues
US6610695B1 (en) 1997-06-19 2003-08-26 Smithkline Beecham Corporation Aryloxy substituted pyrimidine imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
AU8381098A (en) 1997-07-02 1999-01-25 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
EP1041989A4 (fr) 1997-10-08 2002-11-20 Smithkline Beecham Corp Nouveaux composes substitues de cycloalcenyle
AU1924699A (en) 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
US6436960B1 (en) * 1998-02-02 2002-08-20 Lg Chemical Ltd. Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof
CZ20004339A3 (cs) 1998-05-22 2001-10-17 Smithkline Beecham Corporation Nové 2-alkylem substituované imidazolové sloučeniny
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
GB9812523D0 (en) * 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
WO2000016778A1 (fr) * 1998-09-24 2000-03-30 Merck & Co., Inc. Procede de traitement du cancer
ATE258055T1 (de) 1998-11-04 2004-02-15 Smithkline Beecham Corp Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
JP2002540072A (ja) * 1999-03-03 2002-11-26 メルク エンド カムパニー インコーポレーテッド プレニル蛋白トランスフェラーゼの阻害剤
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
NZ518032A (en) 1999-11-22 2004-02-27 Smithkline Beecham Plc Substituted imidazole derivatives
ES2249309T3 (es) 1999-11-23 2006-04-01 Smithkline Beecham Corp Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
ATE296809T1 (de) 1999-11-23 2005-06-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0005357D0 (en) 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
MXPA03002449A (es) 2000-09-21 2003-06-19 Smithkline Beecham Plc Derivados de imidazol como inhibidores de cinasa raf.
WO2002026246A2 (fr) * 2000-09-29 2002-04-04 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions pharmaceutiques contenant des polynucleotides codant une proteine raf
CN1479630A (zh) 2000-10-05 2004-03-03 Q 诱导癌细胞死亡和肿瘤消退的方法
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
WO2003022832A1 (fr) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans et pyrroles inhibiteurs de la kinase raf
AU2002365899B2 (en) * 2001-12-04 2007-09-13 Onyx Pharmaceuticals, Inc. RAF-MEK-ERK pathway inhibitors to treat cancer
EP1707205A2 (fr) 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Compositions pharmaceutiques contenant un antichlinergique et un inhibiteur du p38 pour le traitement de maladies respiratoires
US6878731B2 (en) * 2002-08-14 2005-04-12 Pure World Botanicals, Inc. Imidazole alkaloids from Lepidium meyenii and methods of usage
ES2497116T3 (es) 2002-08-19 2014-09-22 Lorus Therapeutics Inc. Imidazoles 2,4,5-trisustituidos y su uso como agentes antimicrobianos
ATE479683T1 (de) 2002-11-05 2010-09-15 Glaxo Group Ltd Antibakterielle mittel
US7902192B2 (en) 2003-05-15 2011-03-08 Arqule, Inc. Inhibitors of P38 and methods of using the same
WO2005030151A2 (fr) 2003-10-02 2005-04-07 Irm Llc Composes et compositions utiles comme inhibiteurs de la proteine kinase
JP5095216B2 (ja) * 2003-11-14 2012-12-12 ローラス セラピューティクス インコーポレーテッド アリールイミダゾールおよびその抗癌剤としての使用
US7829560B2 (en) 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
US8178672B2 (en) 2004-10-19 2012-05-15 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
AU2006250809B2 (en) 2005-05-25 2011-05-12 Lorus Therapeutics Inc. 2-indolyl imidazo(4,5-D)phenanthroline derivatives and their use in the treatment of cancer
US7598257B2 (en) 2005-12-13 2009-10-06 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
TWI404716B (zh) * 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
PT3070090T (pt) 2007-06-13 2019-03-20 Incyte Holdings Corp Utilização de sais do inibidor da janus cinase (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo
JP5524220B2 (ja) 2008-10-07 2014-06-18 アストラゼネカ・ユーケイ・リミテッド 医薬配合物５１４
US8716303B2 (en) 2009-05-22 2014-05-06 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2761954C (fr) 2009-05-22 2018-07-31 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- ou heptane-nitrile en tant qu'inhibiteurs de jak
WO2011028685A1 (fr) 2009-09-01 2011-03-10 Incyte Corporation Dérivés hétérocycliques de pyrazol-4-yl-pyrrolo[2,3-d] pyrimidines en tant qu'inhibiteurs de janus kinase
HRP20160326T1 (hr) 2010-03-10 2016-05-20 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kao inhibitori jak1
EA035981B1 (ru) 2010-05-21 2020-09-09 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
BR112013032720A2 (pt) 2011-06-20 2016-09-13 Incyte Corp "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados"
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
SG10202111768XA (en) 2012-11-15 2021-11-29 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
HUE042466T2 (hu) 2013-03-06 2019-06-28 Incyte Holdings Corp Eljárás és köztitermékek JAK inhibitor elõállítására
EP2976342A4 (fr) 2013-03-20 2016-08-10 Aptose Biosciences Inc Dérivés d'imidazo[4,5-d]phénanthroline 2-substitués et leur utilisation dans le traitement du cancer
PH12019502074B1 (en) 2013-08-07 2023-10-18 Incyte Holdings Corp Sustained release dosage forms for a jak1 inhibitor
US20150104392A1 (en) 2013-10-04 2015-04-16 Aptose Biosciences Inc. Compositions, biomarkers and their use in the treatment of cancer
WO2015184305A1 (fr) 2014-05-30 2015-12-03 Incyte Corporation Traitement de la leucémie neutrophile chronique (cnl) et de la leucémie myéloïde chronique atypique (acml) par des inhibiteurs de jak1
CA3081261A1 (fr) 2017-10-30 2019-05-09 Aptose Biosciences Inc. Arylimidazoles pour le traitement du cancer
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
WO2019191684A1 (fr) 2018-03-30 2019-10-03 Incyte Corporation Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022249192A1 (fr) * 2021-05-27 2022-12-01 Ramot At Tel-Aviv University Ltd. Composés suppresseurs de métastases à large spectre et leurs utilisations thérapeutiques dans des tumeurs humaines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352705A (en) * 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
IL117580A0 (en) * 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
JP3382951B2 (ja) * 1995-10-06 2003-03-04 メルク エンド カムパニー インコーポレーテッド 抗がん活性及びサイトカン阻害活性を有する置換イミダゾール

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352705A (en) * 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase

Also Published As

Publication number Publication date
CA2250232A1 (fr) 1997-10-09
AU2722197A (en) 1997-10-22
WO1997036587A1 (fr) 1997-10-09
EP0906099A1 (fr) 1999-04-07
JP2000504023A (ja) 2000-04-04
EP0906099A4 (fr) 2001-02-07

Similar Documents

Publication Publication Date Title
AU727939B2 (en) A method of treating cancer
AU701763B2 (en) Inhibitors of farnesyl protein transferase
AU3215197A (en) A method of treating cancer
US5869682A (en) Inhibitors of farnesyl-protein transferase
CA2251955A1 (fr) Methode de traitement de cancer
AU717298B2 (en) Inhibitors of farnesyl-protein transferase
AU700175B2 (en) Thiol-free inhibitors of farnesyl-protein transferase
WO1996034010A2 (fr) Inhibiteurs de la farnesyle transferase
AU716153B2 (en) Inhibitors of farnesyl-protein transferase
US5627202A (en) Inhibitors of farnesyl-protein transferase
WO1997027853A1 (fr) Inhibiteurs de farnesyl-proteine transferase
AU713698B2 (en) Inhibitors of farnesyl-protein transferase
AU708620B2 (en) Inhibitors of farnesyl-protein transferase
WO1996031525A2 (fr) Inhibiteurs de la farnesyl-proteine transferase
CA2201349A1 (fr) Inhibiteurs de transferase de farnesyl-proteine
EP0837857A2 (fr) Inhibiteurs de la farnesyl-proteine transferase
CA2201348A1 (fr) Inhibiteurs de la transferase de proteines farnesylees exempts de thiol
AU2692599A (en) Inhibitors of farnesyl-protein transferase
JPH11502822A (ja) ファルネシル−タンパク質トランスフェラーゼ阻害剤

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired